Yan, X., Peters, G., Sharma, A., Nandy, P., Nessel, C., Garmann, D., … Zhang, L. (2017). The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation. In BLOOD (Vol. 130). Atlanta, GA: AMER SOC HEMATOLOGY.

Yan, Xiaoyu, Gary Peters, Amarnath Sharma, Partha Nandy, Christopher Nessel, Dirk Garmann, Stefan Willmann, et al. “The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation.” In BLOOD, Vol. 130. AMER SOC HEMATOLOGY, 2017.

Yan X, Peters G, Sharma A, Nandy P, Nessel C, Garmann D, et al. The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation. In: BLOOD. AMER SOC HEMATOLOGY; 2017.

Yan, Xiaoyu, et al. “The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation.” BLOOD, vol. 130, AMER SOC HEMATOLOGY, 2017.

Yan X, Peters G, Sharma A, Nandy P, Nessel C, Garmann D, Willmann S, Hermanowski-Vosatka A, Solms A, Berkowitz SD, Spiro TE, Fox KAA, Weitz JI, Schmidt S, Piccini JP, Patel M, Becker RC, Zhang L. The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation. BLOOD. AMER SOC HEMATOLOGY; 2017.